<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800562</url>
  </required_header>
  <id_info>
    <org_study_id>PCS499-NL02</org_study_id>
    <nct_id>NCT04800562</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Processa Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Processa Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo controlled study that will evaluate the efficacy&#xD;
      and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with&#xD;
      necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20&#xD;
      ulcerated NL patients who also meet other inclusion/exclusion criteria will be enrolled in&#xD;
      the study. The primary objective of this study is to evaluate the efficacy of PCS499 as&#xD;
      compared with placebo in ulcerated patients with Necrobiosis Lipoidica.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ulcer closure as assessed by skin exam in patients treated with PCS499 as compared to placebo</measure>
    <time_frame>~ 6 months</time_frame>
    <description>Evaluation of proportion of patients with wound closure based on skin evaluation in patients with NL as compared with placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Necrobiosis Lipoidica</condition>
  <arm_group>
    <arm_group_label>PCS499 900mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCS499 900mg twice a day with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>similar in appearance to active study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCS499</intervention_name>
    <description>PCS499 900mg twice a day with food</description>
    <arm_group_label>PCS499 900mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients age 18 to 80 years of age, inclusive, at Screening.&#xD;
&#xD;
          2. Biopsy-confirmed diagnosis of NL. Biopsies of continually active lesions performed&#xD;
             outside of this clinical study will need to be reviewed and the diagnosis confirmed by&#xD;
             the study pathologist. For patients with no previous history of biopsy, no biopsy&#xD;
             within the previous 5 years, a biopsy that is not confirmed to be NL, or newly active&#xD;
             lesion, a biopsy to confirm a diagnosis of NL will be performed at the Screening&#xD;
             visit.&#xD;
&#xD;
          3. Ulcers on a single leg (&quot;reference leg&quot;) at Baseline should consist of at least one&#xD;
             (1) ulcer with a minimum ulcer surface area of 1 cm2, total ulcer area of a minimum of&#xD;
             2 cm2, and no more than 6 ulcers. If ulcers are present on both legs, the Investigator&#xD;
             will select the &quot;reference leg&quot;. The ulcer(s) on the reference leg (&quot;reference&#xD;
             ulcers&quot;) and all other ulcers associated with the patient's NL (&quot;other ulcers&quot;)&#xD;
             present at the Baseline visit will be followed in the study.&#xD;
&#xD;
          4. Women of childbearing potential must have a negative serum pregnancy test at the&#xD;
             Screening Visit and a negative urine pregnancy test at Baseline before dosing. Women&#xD;
             of childbearing potential must use one of the following acceptable methods of&#xD;
             contraception throughout the study: oral contraceptive medication, intrauterine device&#xD;
             (IUD), hormonal implants, injectable contraceptive medications, double-barrier&#xD;
             methods, or tubal ligation.&#xD;
&#xD;
          5. Females who are postmenopausal (age-related amenorrhea &gt;= 12 consecutive months and&#xD;
             increased follicle-stimulating hormone [FSH] &gt; 40 mIU/mL. If necessary to confirm&#xD;
             postmenopausal status, an FSH will be drawn at Screening) or who have undergone&#xD;
             hysterectomy or bilateral oophorectomy are exempt from pregnancy testing.&#xD;
&#xD;
          6. Male patients must be willing to use appropriate contraceptive measures and refrain&#xD;
             from sexual activity with any female who is pregnant or lactating.&#xD;
&#xD;
          7. Patient must be willing and able to swallow whole tablets.&#xD;
&#xD;
          8. Patient must be willing and able to comply with study procedures.&#xD;
&#xD;
          9. Patient must be willing and able to provide signed, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or previous (within 4 weeks of Baseline) treatment with:&#xD;
&#xD;
               1. Oral corticosteroids.&#xD;
&#xD;
               2. Topical drugs (including prescription and over-the counter) on the reference leg.&#xD;
                  (Topical non-medicated moisturizer treatment products can be administered);&#xD;
&#xD;
               3. Systemic pentoxifylline, theophylline, or cilostazol.&#xD;
&#xD;
               4. Oral retinoid.&#xD;
&#xD;
               5. Other systemic immunosuppressant or immunomodulatory drugs, including but not&#xD;
                  limited to calcineurin inhibitors (e.g., tacrolimus), thalidomide, apremilast,&#xD;
                  anti-malarials (e.g., hydroxychloroquine, chloroquine), cyclosporine,&#xD;
                  mycophenolate mofetil, azathioprine, methotrexate, etc.&#xD;
&#xD;
          2. Current or previous (within 12 weeks of Baseline) treatment with any biologic therapy&#xD;
             (e.g., adalimumab, etanercept, infliximab, anakinra, etc.).&#xD;
&#xD;
          3. Phototherapy/photochemotherapy (NBUVB, UVB, PUVA) within 6 weeks prior to Baseline&#xD;
&#xD;
          4. Skin grafting, or other surgical procedure (other than debridement) within 6 weeks&#xD;
             prior to Baseline.&#xD;
&#xD;
          5. History of drug allergy, including but not limited to pentoxifylline or other xanthine&#xD;
             derivatives, or other allergy, which in the opinion of the Investigator,&#xD;
             contraindicates participation.&#xD;
&#xD;
          6. Anticipated concurrent use of a strong CYP1A2 inhibiting drug, including but not&#xD;
             limited to cimetidine and/or fluvoxamine, during the course of the study (after&#xD;
             Screening).&#xD;
&#xD;
          7. Fever (&gt;38°C), or chronic, persistent, or recurring infection(s) at Screening or&#xD;
             Baseline.&#xD;
&#xD;
          8. Any infection requiring oral antimicrobial therapy within 2 weeks prior to Baseline or&#xD;
             any infection requiring parenteral antibiotics or hospitalization within 12 weeks&#xD;
             prior to Baseline. Any treatment for such infections must have been completed and the&#xD;
             infection cured for at least 2 weeks prior to Baseline.&#xD;
&#xD;
          9. History of sarcoidosis, pyoderma gangrenosum, or any other disorder (in the judgment&#xD;
             of the Investigator) that would interfere with the evaluation of NL or require&#xD;
             protocol prohibited medication.&#xD;
&#xD;
         10. History of any life threatening infection or sepsis within 12 months of Baseline:&#xD;
&#xD;
         11. Clinically significant cardiac disease including but not limited to unstable angina,&#xD;
             acute myocardial infarction within 6 months of Baseline, and arrhythmia requiring&#xD;
             therapy.&#xD;
&#xD;
         12. Patient has QTc interval ≥ 480 milliseconds on Screening Electrocardiogram (ECG); a&#xD;
             second Screening ECG may be done at investigator's discretion but the average of the&#xD;
             two QTc screening intervals must not be ≥ 480 milliseconds.&#xD;
&#xD;
         13. History of cerebral hemorrhage, cerebrovascular accident, transient ischemic attack,&#xD;
             gastrointestinal bleeding, or retinal hemorrhage within 6 months of Baseline.&#xD;
&#xD;
         14. Patient has active or history of neoplastic disease (except for adequately treated&#xD;
             non-invasive basal cell and/or squamous cell carcinoma or carcinoma in situ of the&#xD;
             cervix) within the past 5 years prior to Baseline.&#xD;
&#xD;
         15. Presence of clinically significant medical condition(s) including but not limited to:&#xD;
             renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary,&#xD;
             neurological, psychiatric, substance abuse, and/or any other clinically significant&#xD;
             disease or disorder, which in the opinion of the Investigator (by its nature or by&#xD;
             being inadequately controlled), may put the patient at risk due to participation in&#xD;
             the study, influence the results of the study, and/or affect the patient's ability to&#xD;
             complete the study.&#xD;
&#xD;
         16. History of or current diagnosis of active tuberculosis (TB); undergoing treatment for&#xD;
             latent TB infection (LTBI); untreated LTBI (as determined by documented results within&#xD;
             3 months of the Screening Visit of a positive TB skin test with purified protein&#xD;
             derivative with induration &gt;= 5 millimeter (mm), or a positive QuantiFERON-TB test or&#xD;
             positive or borderline T-Spot [Elispot] test); or positive TB test at Screening.&#xD;
             Subjects with documented completion of appropriate LTBI treatment would not be&#xD;
             excluded and are not required to be tested.&#xD;
&#xD;
         17. Vaccination with live or live-attenuated virus vaccine within 1 month prior to&#xD;
             Baseline.&#xD;
&#xD;
         18. The results of the following laboratory tests performed at the central laboratory at&#xD;
             Screening meet any of the criteria below:&#xD;
&#xD;
               1. Hemoglobin &lt; 8.0 g/dL (International System of Units (SI): &lt; 80 g/L);&#xD;
&#xD;
               2. White blood cells &lt; 3.0 x 10^3 cells/mm^3 (SI: &lt; 3.0 x 10^9 cells/L);&#xD;
&#xD;
               3. Neutrophils &lt; 1.0 x 10^3 cells/mm^3 (SI: &lt; 1.0 x 10^9 cells/L);&#xD;
&#xD;
               4. Lymphocytes &lt; 0.5 x 10^3 cells/mm^3 (SI: &lt; 0.5 x 10^9 cells/L);&#xD;
&#xD;
               5. Platelets &lt; 100 x 10^3 cells/mm^3 (SI: &lt; 100 x 10^9 cells/L)&#xD;
&#xD;
               6. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or alkaline&#xD;
                  phosphatase (ALP) ≥ 2 x upper limit of normal (ULN);&#xD;
&#xD;
               7. Total bilirubin level ≥ 2 x ULN unless the individual has been diagnosed with&#xD;
                  Gilbert's disease and this is clearly documented;&#xD;
&#xD;
               8. Estimated glomerular filtration rate &lt; 40 mL/min/1.73 m^2 based on the&#xD;
                  Modification of Diet in Renal Disease (MDRD) formula.&#xD;
&#xD;
               9. HbA1c &gt; 10%&#xD;
&#xD;
              10. Positive HIV serology&#xD;
&#xD;
              11. Evidence of active Hepatitis B Virus (HBV) infection&#xD;
&#xD;
              12. Evidence of active Hepatitis C Virus (HCV) infection&#xD;
&#xD;
         19. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         20. Patient unwilling or unable to swallow tablets whole.&#xD;
&#xD;
         21. Any other medical condition, serious intercurrent illness, or extenuating circumstance&#xD;
             that, in the opinion of the Investigator, would preclude participation in the study.&#xD;
&#xD;
         22. Use of any investigational product within 30 days prior to Baseline or currently&#xD;
             enrolled in another study that involves clinical investigations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sian Bigora, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Processa Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Nyberg</last_name>
    <phone>443-776-3133</phone>
    <email>mnyberg@processapharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vega</last_name>
      <phone>858-278-8470</phone>
      <phone_ext>3</phone_ext>
      <email>carlos@univct.com</email>
    </contact>
    <investigator>
      <last_name>Walter Nahm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Klemme</last_name>
      <phone>507-266-7838</phone>
      <email>klemme.gabrielle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Afsaneh Alavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Sparks</last_name>
      <phone>215-662-3837</phone>
      <email>shelby.sparks@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Misha Rosenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Serena</last_name>
      <phone>412-355-0764</phone>
      <email>lserena@serenagroups.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristy Breisinger</last_name>
      <phone>1-412-956-3574</phone>
      <email>kbreisinger@serenagroups.com</email>
    </contact_backup>
    <investigator>
      <last_name>Keyur Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Kiser</last_name>
      <phone>843-556-8886</phone>
      <email>jonathan@dermandlaser.com</email>
    </contact>
    <investigator>
      <last_name>Todd Schlesinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Benitez-Rivera</last_name>
      <phone>414-955-2846</phone>
      <email>dbenitez@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Karolyn Wanat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Stepanenko</last_name>
      <phone>+380504430205</phone>
      <email>stepanenkorl@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Viktor I Stepanenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04209</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daria Luk</last_name>
      <phone>+380509361935</phone>
      <email>lukdasa97@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bohdan Lytvynenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavlo Lykhovyd</last_name>
      <phone>+380976131169</phone>
      <email>p.lykhovyd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oleh Nadashkevych</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Processa Clinical Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Kardash</last_name>
      <phone>+380677362900</phone>
      <email>kardashdermatology@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nataliya Reznichenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrobiosis Lipoidica</mesh_term>
    <mesh_term>Necrobiotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

